BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Christian L. Barrett, Richard B. Schwab, HyunChul Jung, Brian Crain, Daniel J. Goff, Catriona H. M. Jamieson, Patricia A. Thistlethwaite, Olivier Harismendy, Dennis A. Carson, Kelly A. Frazer, Marc Lenburg. Transcriptome Sequencing of Tumor Subpopulations Reveals a Spectrum of Therapeutic Options for Squamous Cell Lung CancerPLoS ONE 2013; 8(3): e58714 doi: 10.1371/journal.pone.0058714
2
Bruno Christian Koehler, Anna-Lena Scherr, Stephan Lorenz, Toni Urbanik, Nicole Kautz, Christin Elssner, Stefan Welte, Justo Lorenzo Bermejo, Dirk Jäger, Henning Schulze-Bergkamen, Jun Li. Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In VitroPLoS ONE 2013; 8(10): e76446 doi: 10.1371/journal.pone.0076446
3
Yinglan Liu, Yingwei Wang, Yaling Zhang, Jianhua Fu, Guangmei Zhang. Knockdown of HMGA1 expression by short/small hairpin RNA inhibits growth of ovarian carcinoma cellsBiotechnology and Applied Biochemistry 2012; 59(1): 1 doi: 10.1002/bab.56
4
Inga Hochnadel, Uta Kossatz-Boehlert, Nils Jedicke, Henrike Lenzen, Michael P. Manns, Tetyana Yevsa. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancersHuman Vaccines & Immunotherapeutics 2017; 13(12): 2931 doi: 10.1080/21645515.2017.1359362
5
Darren Finlay, Robyn D. Richardson, Lisa K. Landberg, Amy L. Howes, Kristiina Vuori, Andrei L. Gartel. Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic AxisPLoS ONE 2010; 5(10): e13375 doi: 10.1371/journal.pone.0013375
6
Inas Almazari, Young-Joon Surh. Natural Products in Cancer Prevention and TherapyTopics in Current Chemistry 2012; 329: 35 doi: 10.1007/128_2012_344
7
KEIICHIRO NOJIRI, KAZUSHI SUGIMOTO, KATSUYA SHIRAKI, MASAHIKO TAMEDA, YUUJI INAGAKI, SUGURU OGURA, CHIKA KASAI, SATOKO KUSAGAWA, MISAO YONEDA, NORIHIKO YAMAMOTO, YOSHIYUKI TAKEI, TSUTOMU NOBORI, MASAAKI ITO. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinomaInternational Journal of Oncology 2013; 42(1): 101 doi: 10.3892/ijo.2012.1676
8
Wei Jiang, Dong-Bo Wu, Si-Yu Fu, En-Qiang Chen, Hong Tang, Tao-You Zhou. Insight into the role of TRAIL in liver diseasesBiomedicine & Pharmacotherapy 2019; 110: 641 doi: 10.1016/j.biopha.2018.12.004
9
Alvaro Mordente, Elisabetta Meucci, Andrea Silvestrini, Giuseppe Ettore Martorana, Bruno Giardina. Advances in Mitochondrial MedicineAdvances in Experimental Medicine and Biology 2012; 942: 385 doi: 10.1007/978-94-007-2869-1_18
10
T Lu, N Shao, C Ji. Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cellsCancer Gene Therapy 2013; 20(1): 33 doi: 10.1038/cgt.2012.81
11
ZHAOJUN WAN, HUAZHENG PAN, SHIHAI LIU, JINGJUAN ZHU, WEIWEI QI, KAI FU, TENG ZHAO, JUN LIANG. Downregulation of SNAIL sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by regulating the NF-κB pathwayOncology Reports 2015; 33(3): 1560 doi: 10.3892/or.2015.3743
12
T. Ciuleanu, I. Bazin, D. Lungulescu, L. Miron, I. Bondarenko, A. Deptala, M. Rodriguez-Torres, B. Giantonio, N.L. Fox, P. Wissel, J. Egger, M. Ding, R.N. Kalyani, R. Humphreys, M. Gribbin, W. Sun. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaAnnals of Oncology 2016; 27(4): 680 doi: 10.1093/annonc/mdw004
13
Yuki Haga, Tatsuo Kanda, Masato Nakamura, Shingo Nakamoto, Reina Sasaki, Koji Takahashi, Shuang Wu, Osamu Yokosuka, Olorunseun Ogunwobi. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell linesPLOS ONE 2017; 12(3): e0174153 doi: 10.1371/journal.pone.0174153
14
Jorn Markus Schattenberg, Marcus Schuchmann, Peter Robert Galle. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathwaysJournal of Gastroenterology and Hepatology 2011; 26: 213 doi: 10.1111/j.1440-1746.2010.06582.x
15
Martin Franz Sprinzl, Florian Reisinger, Andreas Puschnik, Marc Ringelhan, Kerstin Ackermann, Daniel Hartmann, Matthias Schiemann, Arndt Weinmann, Peter Robert Galle, Marcus Schuchmann, Helmut Friess, Gerd Otto, Mathias Heikenwalder, Ulrike Protzer. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cellsHepatology 2013; 57(6): 2358 doi: 10.1002/hep.26328
16
Dawei Zhang, Jianping Liu, Yang Wang, Jie Chen, Tao Chen. shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosisJournal of Cellular Biochemistry 2011; 112(11): 3140 doi: 10.1002/jcb.23240
17
M Siegemund, N Pollak, O Seifert, K Wahl, K Hanak, A Vogel, A K Nussler, D Göttsch, S Münkel, H Bantel, R E Kontermann, K Pfizenmaier. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivityCell Death & Disease 2012; 3(4): e295 doi: 10.1038/cddis.2012.29
18
Bruno Christian Koehler, Adam Jassowicz, Anna-Lena Scherr, Stephan Lorenz, Praveen Radhakrishnan, Nicole Kautz, Christin Elssner, Johanna Weiss, Dirk Jaeger, Martin Schneider, Henning Schulze-Bergkamen. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signalingBMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1929-y
19
Venturina Stagni, Simonetta Santini, Daniela Barilà. A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM KinaseCancers 2012; 4(2): 354 doi: 10.3390/cancers4020354
20
Guan Wang, Yao Zhan, Haiqing Wang, Wenhua Li. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic proteinCancer Chemotherapy and Pharmacology 2012; 69(3): 799 doi: 10.1007/s00280-011-1763-0
21
Kuen-Feng Chen, Hui-Ling Chen, Chung-Wai Shiau, Chun-Yu Liu, Pei-Yi Chu, Wei-Tien Tai, Kimihisa Ichikawa, Pei-Jer Chen, Ann-Lii Cheng. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibodyBritish Journal of Pharmacology 2013; 168(3): 658 doi: 10.1111/j.1476-5381.2012.02212.x
22
Gianluigi Giannelli, Bhavna Rani, Francesco Dituri, Yuan Cao, Giuseppe Palasciano. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironmentGut 2014; 63(10): 1668 doi: 10.1136/gutjnl-2014-307323